Gerardo Autran Cavalcante Araújo

Gerardo Autran Cavalcante Araújo

Auto-generated profile, based on publicly available information

Gerardo Autran Cavalcante Araújo

Department of Medicine, School of Medicine, Federal University of Ceará, Fortaleza, Brazil

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 October 2025 in Intestinal Research
Verified
Journal Article
Open access
PDF file
HFHumberto Barbosa da Costa Filho
Humberto Barbosa da Costa Filho
GAGerardo Autran Cavalcante Araújo
Gerardo Autran Cavalcante Araújo
TSThiago Meneses Araújo Leite Sales
Thiago Meneses Araújo Leite Sales
SPSuliana Mesquita Paula
Suliana Mesquita Paula
MCMarco Antonio de Freitas Clementino
Marco Antonio de Freitas Clementino
MSMarcellus Henrique Loiola Ponte Souza
Marcellus Henrique Loiola Ponte Souza
Background/Aims: Inflammatory bowel disease can be triggered by disturbances in intestinal mucosal integrity, leading to bacterial transmigration. The treatment of inflammatory bowel diseases must not only aim to reduce inflammation, but also to reverse the damage to mucosal barrier function. Janus kinase (JAK) inhibitors have been used to treat inflammatory diseases, including ulcerative colitis. However, little is known about the ability of this class of drugs to reverse the loss of mucosal integrity. This study evaluated the effects of tofacitinib, a JAK pathway inhibitor, on inflammation and colonic mucosal integrity in a rat model of 2,4,6-trinitrobenzenesulfonic acid (TNBS)-induced colitis. Methods: Colitis was induced in Wistar rats via rectal administration of TNBS (20 mg+50% ethanol). The control group received only saline. The animals were pretreated with tofacitinib (15 mg/kg) or saline 30 minutes before induction and twice daily thereafter. Seven days after induction, the animals were euthanized, the colon was removed, and myeloperoxidase activity, baseline transepithelial electrical resistance (TER), TER after 1 hour, and fluorescein permeability were assessed. Tight junction proteins in the colon (claudin-2, claudin-15, and tricellulin) were detected using Western blotting. Results: Tofacitinib treatment significantly reduced (P< 0.05) the inflammatory parameters and preserved the integrity of the intestinal epithelial barrier compared with the colitis group (P< 0.05), increased baseline TER, reduced the drop in TER after 1 hour, and decreased paracellular permeability to fluorescein by reducing claudin-2 and claudin-15 expression. Conclusions: JAK inhibition by tofacitinib restored colonic barrier function through antiinflammatory effects and decreased claudin-2 and claudin-15 expressions.